44,946 results match your criteria Lymphoma Non-Hodgkin

Geographic clustering of cutaneous T-cell lymphoma in New Jersey: an exploratory analysis using residential histories.

Cancer Causes Control 2021 Jun 12. Epub 2021 Jun 12.

Department of Health, New Jersey State Cancer Registry, Trenton, NJ, USA.

Purpose: Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma. Previous studies have reported geographic clustering of CTCL based on the residence at the time of diagnosis. We explore geographic clustering of CTCL using both the residence at the time of diagnosis and past residences using data from the New Jersey State Cancer Registry. Read More

View Article and Full-Text PDF

NK-/T-cell lymphomas.

Leukemia 2021 Jun 11. Epub 2021 Jun 11.

Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, PR China.

Natural killer/T-cell lymphoma (NKTL) is a sub-type of Epstein-Barr virus (EBV)-related non-Hodgkin lymphomas common in Asia and Latin America but rare elsewhere. Its pathogenesis is complex and incompletely understood. Lymphoma cells are transformed from NK- or T-cells, sometimes both. Read More

View Article and Full-Text PDF

Hypercalcemia and bulky primary adrenal non-Hodgkin lymphoma: A case report.

Med Clin (Barc) 2021 Jun 8. Epub 2021 Jun 8.

Department of General and Digestive Surgery. Hospital Universitario Virgen de Valme, Sevilla, Spain.

View Article and Full-Text PDF

Overall and event-free survival of childhood lymphoma in Greece: analysis of harmonized clinical data over a 24-year active registration period.

Leuk Lymphoma 2021 Jun 11:1-13. Epub 2021 Jun 11.

Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

We assessed event-free (EFS) and overall (OS) survival in 676 incident cases of childhood Hodgkin (HL) and non-Hodgkin (NHL) lymphoma actively registered in Greece (1996-2019). HL-OS was 96% and NHL-OS 85%, whereas HL-EFS was 86% and NHL-EFS was 81%, notably similar to the respective OS rates (HL: 95%, NHL: 85%) in developed countries. For HL, older age at diagnosis, high maternal education and close proximity to treatment centers were linked to remarkably favorable outcomes. Read More

View Article and Full-Text PDF

The pathologic diagnosis of mantle cell lymphoma.

Histol Histopathol 2021 Jun 11:18351. Epub 2021 Jun 11.

Department of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Mantle cell lymphoma (MCL) is a mature B-cell non-Hodgkin lymphoma usually characterized by t(11;14) (q13;q32), or CCND1 translocation and Cyclin D1 over expression. A very small subset of MCL may lack the t(11;14) (q13;q32) translocation and Cyclin D1 over expression, but show alternative translocations involving CCND2 and CCND3, and over expression of SOX11. In general, MCL has been considered a very aggressive and incurable lymphoma and patients with MCL usually have a poor prognosis. Read More

View Article and Full-Text PDF

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.

Front Oncol 2021 25;11:664421. Epub 2021 May 25.

Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.

Background: The use of T cells expressing chimeric antigen receptor (CAR T) engineered to target CD19 constitutes breakthrough treatment for relapsed or refractory B cell non-Hodgkin lymphoma (R/R B-NHL). Despite improved outcomes, high relapse rate remains a challenge to overcome. Here, we report the clinical results and the pharmacokinetics of bispecific CD19/22 CAR T in patients with R/R B-NHL. Read More

View Article and Full-Text PDF

Genetically Engineered Mouse Models Support a Major Role of Immune Checkpoint-Dependent Immunosurveillance Escape in B-Cell Lymphomas.

Front Immunol 2021 25;12:669964. Epub 2021 May 25.

UMR CNRS 7276/INSERM U1262 CRIBL, University of Limoges, Limoges, France.

These last 20 years, research on immune tumor microenvironment led to identify some critical recurrent mechanisms used in cancer to escape immune response. Through immune checkpoints, which are cell surface molecules involved in the immune system control, it is now established that tumor cells are able to shutdown the immune response. Due to the complexity and heterogeneity of Non Hodgkin B-cell Lymphomas (NHBLs), it is difficult to understand the precise mechanisms of immune escape and to explain the mitigated effect of immune checkpoints blockade for their treatment. Read More

View Article and Full-Text PDF

Summary of the 12 Most Common Cancers in the CancerLinQ Discovery (CLQD) Database.

JCO Clin Cancer Inform 2021 Jun;5:658-667

CancerLinQ, American Society of Clinical Oncology, Alexandria, VA.

Purpose: In 2014, the ASCO developed CancerLinQ (CLQ), a health technology platform for oncology. The CLQ Discovery (CLQD) database was created to make data available for research and this paper provides a summary of this database.

Methods: This study described the clinical and demographic characteristics of the 12 most common cancers in the CLQD database. Read More

View Article and Full-Text PDF

Allogeneic stem cell transplant in non-Hodgkin lymphomas: Still an indication?

Peter Dreger

Hematol Oncol 2021 Jun;39 Suppl 1:100-103

Department of Medicine V, University of Heidelberg, Heidelberg, Germany.

Allogeneic hematopoietic cell transplantation (alloHCT) used to play a defined role in the treatment of non-Hodgkin lymphoma (NHL). With the advent of modern targeted molecular therapies and immunotherapies, treatment standards at least for B-cell lymphoma have undergone significant changes, thereby questioning the traditional role of alloHCT in these diseases. This paper attempts to describe the current place and the perspectives of alloHCT in the rapidly evolving treatment landscape of NHL. Read More

View Article and Full-Text PDF

High-risk follicular lymphoma: Treatment options.

Brad Kahl

Hematol Oncol 2021 Jun;39 Suppl 1:94-99

Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma in the Western hemisphere. The natural history of FL appears to have been favorably impacted by the introduction of rituximab. Randomized clinical trials have demonstrated that the addition of rituximab to standard chemotherapy induction has improved the overall survival. Read More

View Article and Full-Text PDF

[Analysis of Predictive Value of Laboratory Indexes for Malignant Lymphoma Patients with Bone Marrow Involvement].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):763-771

Department of Hematology, Wanbei Coal and Electricity Group General Hospital, Suzhou 234011, Anhui Province, China.

Objective: To analyze the influence of bone marrow involvement (BMI) in patients with malignant lymphoma (ML) on laboratory indexes, and evaluate the laboratory markers that can be used to predict/diagnose BMI.

Methods: The clinical characteristics and laboratory indexes of 137 ML patients were analyzed retrospectively, from which the indexes of BMI in ML patients was studied. The logistic regression analysis and receiver operating curve (ROC) were used to evaluate independent risk factors and predictors of BMI diagnosis in ML patients. Read More

View Article and Full-Text PDF

[Clinical Characteristics and Risk Factors of Nosocomial Infection in 472 Patients with Non-Hodgkin Lymphoma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):751-756

Department of Laboratorial Medicine,The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China.

Objective: To investigate the clinical characteristics and risk factors of nosocomial infection in patients with non-Hodgkin lymphoma (NHL), in order to guide better clinical prevention and treatment of nosocomial infection.

Methods: The incidence of nosocomial infection, infection site, characteristics of pathogenic bacteria, drug sensitivity test results and infection risk factors of 472 non-Hodgkin lymphoma patients admitted to the Second Affiliated Hospital of Fujian Medical University from January 2015 to September 2020 were retrospectively analyzed.

Results: Among the 472 patients, 97 (20. Read More

View Article and Full-Text PDF

Dietary trans-fatty acid intake in relation to cancer risk: a systematic review and meta-analysis.

Nutr Rev 2021 Jun;79(7):758-776

Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.

Context: Apart from ruminant fat, trans-fatty acids are produced during the partial hydrogenation of vegetable oils, (eg, in the production of ultraprocessed foods). Harmful cardiovascular effects of trans-fatty acids are already proven, but the link with cancer risk has not yet been summarized.

Objective: A systematic review (following PRISMA guidelines) - including observational studies on the association of trans-fatty acid intake with any cancer risk - was conducted, with no limitations on population types. Read More

View Article and Full-Text PDF

Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL Patients.

medRxiv 2021 Jun 3. Epub 2021 Jun 3.

Patients with hematologic malignancies are a high priority for SARS-CoV-2 vaccination, yet the benefit they will derive is uncertain. We investigated the humoral response to vaccination in 53 non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), or CLL patients. Peripheral blood was obtained 2 weeks after first vaccination and 6 weeks after second vaccination for antibody profiling using the multiplex bead-binding assay. Read More

View Article and Full-Text PDF

R-CHOP Chemotherapy for Disseminated Complex Disease due to Anti-Interferon-Gamma Autoantibodies: A Case Report.

Open Forum Infect Dis 2021 Jun 10;8(6):ofab181. Epub 2021 Apr 10.

Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.

A 77-year-old Japanese man with disseminated complex (MAC) disease due to anti-interferon-gamma autoantibodies received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy because of non-Hodgkin lymphoma complication. The hepatobiliary nodules due to MAC resolved with R-CHOP and multidrug antimycobacterial treatment. R-CHOP could serve as an alternative adjunctive therapy for patients with anti-interferon-gamma autoantibodies. Read More

View Article and Full-Text PDF

Clinical Presentation, Renal Histopathological Findings, and Outcome in Patients with Monoclonal Gammopathy and Kidney Disease.

Int J Nephrol 2021 12;2021:8859340. Epub 2021 May 12.

Surgical, Medical and Dental Department of Morphological Sciences, Section of Nephrology, University of Modena and Reggio Emilia, Modena, Italy.

Monoclonal gammopathies are associated with acute and chronic kidney injury. Nephrotoxicity of the secreted monoclonal (M)-protein is related to its biological properties and blood concentration. Little is known about epidemiology, clinical manifestations, and outcome of monoclonal gammopathies in patients with kidney disease. Read More

View Article and Full-Text PDF

Burkitt lymphoma of the head and neck: An international collaborative study.

J Oral Pathol Med 2021 Jun 5. Epub 2021 Jun 5.

Oral Diagnosis Department, Semiology and Oral Pathology, Piracicaba Dental School, University of Campinas, Piracicaba, Brazil.

Background: Burkitt lymphoma (BL) is an aggressive B-cell lymphoma with three variants (endemic, sporadic, and immunodeficiency-associated), presenting with specific epidemiological and clinical features. Burkitt lymphoma affects the head and neck region (BLHN) in approximately 10% of cases. The aim of this study was to undertake a comparative analysis of the clinicopathologic and immunohistochemical (IHC) features of BLHN diagnosed in patients from Africa, Guatemala, and Brazil. Read More

View Article and Full-Text PDF

Oral and oropharyngeal lymphomas: a multi-institutional collaborative study.

J Oral Pathol Med 2021 Jun 6. Epub 2021 Jun 6.

Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

Background: Lymphomas in the oral and oropharyngeal regions are relatively uncommon and their diagnosis is challenging and complex due to the myriad histopathological subtypes. Herein, we report a large series of oral and oropharyngeal lymphomas and compare our data with the currently available literature.

Methods: All cases diagnosed as lymphomas affecting the oral and oropharyngeal regions were retrospectively retrieved from seven Brazilian institutions. Read More

View Article and Full-Text PDF

Mature t/nk-cell lymphomas of the oral and maxillofacial region: a multi-institutional collaborative study.

J Oral Pathol Med 2021 Jun 5. Epub 2021 Jun 5.

Department of Oral Diagnosis and Pathology, School of Dentistry, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

Background: The diagnosis of oral and maxillofacial mature T/NK-cell neoplasms is challenging because of their rarity, morphological heterogeneity and complex immunophenotype, with scarce available data describing their clinical and microscopic aspects. Therefore, in this study we investigated a series of mature T/NK-cell neoplasms affecting this anatomical region and provided an updated literature review.

Methods: Cases diagnosed as mature T/NK cell lymphomas affecting the oral and maxillofacial region were retrospectively retrieved from six pathology files and their diagnoses were confirmed using haematoxylin and eosin-stained slides, immunohistochemical reactions and in situ hybridization for Epstein-Barr virus (EBV) detection. Read More

View Article and Full-Text PDF

Long-term Follow-up and Correlative Analysis of two Phase 2 Trials of Rituximab and Lenalidomide followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma.

Clin Cancer Res 2021 Jun 4. Epub 2021 Jun 4.

Department of Dermatology, University of California Davis School of Medicine.

Purpose: Rituximab and lenalidomide is effective for previously untreated and relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). However, long-term survival and predictive biomarkers are not well-described.

Methods: We conducted two phase 2 open-label trials involving 60 patients with previously untreated and R/R advanced stage iNHL. Read More

View Article and Full-Text PDF

Epstein-Barr virus positive diffuse large B-cell lymphoma transformed into angioimmunoblastic T-cell lymphoma after treatment.

Clin Case Rep 2021 May 5;9(5):e04083. Epub 2021 May 5.

Department of Pathology Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment Chongqing University Cancer Hospital Chongqing China.

Angioimmunoblastic T-cell lymphoma (AITL) is the subtype of mature T-cell non-Hodgkin lymphoma. Compared with diffuse large B-cell lymphoma (DLBCL), AITL patients are frequently accompanied with Epstein-Barr virus (EBV) infection. To date, there is no report on the subsequent development of AITL in patients with EBV-positive DLBCL. Read More

View Article and Full-Text PDF

Primary Esophageal Small Cell Carcinoma Masquerading as Non-Hodgkin Lymphoma in a Young Patient.

Anticancer Res 2021 Jun;41(6):3023-3027

Department of Pulmonology and Critical Care, Allegheny Health Network, Pittsburgh, PA, U.S.A.

Background/aim: Small cell cancer of the esophagus (SCCE) is an extremely rare entity with an aggressive clinical course, thus early diagnosis and treatment are important for improved survival.

Case Report: A 35-year-old male presented with dysphagia, loss of appetite and weight loss. Diagnostic workup revealed an esophageal mass, which was diagnosed as primary non-Hodgkin lymphoma (NHL) on initial biopsy. Read More

View Article and Full-Text PDF

Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase 1, First-in-Human Study.

Clin Cancer Res 2021 Jun 3. Epub 2021 Jun 3.

Haematology, Peter MacCallum Centre, Melbourne.

Purpose: We previously reported a 44% overall response rate (ORR) with venetoclax in a phase 1 study of relapsed/refractory NHL. Complete remission (CR) was observed in patients with mantle cell lymphoma ([MCL], 21%, n=6/28) and follicular lymphoma ([FL], 17%, n=5/29), and partial response (PR) noted in several patients with Waldenström macroglobulinemia (WM), and marginal zone lymphoma (MZL). Here, we report the long-term outcomes of these four cohorts. Read More

View Article and Full-Text PDF

Merkel cell carcinoma patients with solid organ transplant or hematologic malignancy: demographics, survival, and prognosticators.

J Am Acad Dermatol 2021 May 31. Epub 2021 May 31.

Veterans Affairs Palo Alto Healthcare System, Palo Alto, California; Department of Dermatology, Stanford University School of Medicine, Palo Alto, California. Electronic address:

View Article and Full-Text PDF

[Diffuse large B-cell lymphoma: a revolutionary treatment based on genetically-modified immune cells called CAR T cells].

Rev Med Liege 2021 May;76(5-6):476-481

Service d'Hématologie, CHU Liège, Belgique.

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Firstline immunochemotherapy cures approximatively 60 % of patients. The prognosis of patients with refractory disease or with relapsed disease within the first two years after the end of treatment is highly unfavourable. Read More

View Article and Full-Text PDF

Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib.

Onco Targets Ther 2021 24;14:3367-3372. Epub 2021 May 24.

Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, People's Republic of China.

Primary central nervous system lymphoma (PCNSL) is a rare subtype of extranodal non-Hodgkin lymphoma, and the most frequent histological type is diffuse large B-cell lymphoma (DLBCL). Bruton's tyrosine kinase inhibitor (BTKi) has shown clinical activity in DLBCL. We herein report a 53-year-old man who presented with binocular diplopia, gait instability, dizziness and bucking. Read More

View Article and Full-Text PDF

Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab.

Infect Agent Cancer 2021 Jun 2;16(1):38. Epub 2021 Jun 2.

Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS, Naples, Italy.

Patients with non-hodgkin lymphomas (NHL) represent a population of special interest during the current Coronavirus disease-19 (COVID-19) pandemics. NHLs are associated with disease- and treatment-related immunodeficiencies which may generate unusual COVID-19 dynamics and pose unique management challenges. We report the unusual clinical course of COVID-19 in a patient with mantle cell lymphoma (MCL) exposed to nine doses of Rituximab shortly before infection with severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). Read More

View Article and Full-Text PDF

[Advances in clinical and molecular pathology of lymphoma].

W C Li

Zhonghua Bing Li Xue Za Zhi 2021 Jun;50(6):557-559

Department of Pathology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

View Article and Full-Text PDF

Mediastinal Lymphoproliferative Disorders.

Adv Anat Pathol 2021 Jun 2. Epub 2021 Jun 2.

Department of Pathology and Laboratory Services, University of Arkansas for Medical Sciences, Little Rock, AR.

Lymphoproliferative disorders comprise 50% to 60% of all mediastinal malignancies in both children and adults. Primary mediastinal involvement is rare (∼5%), whereas secondary mediastinal involvement by systemic disease is more common (10% to 25%). Primary mediastinal disease is defined as involvement by a lymphoproliferative disorder of mediastinal lymph nodes, the thymus, and/or extranodal mediastinal organs without evidence of systemic disease at presentation. Read More

View Article and Full-Text PDF

Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL.

Cancers (Basel) 2021 May 28;13(11). Epub 2021 May 28.

Department of Medicine, Hematology and Oncology, Ruhr University Bochum, Universitätsklinikum Knappschaftskrankenhaus Bochum GmbH, 44892 Bochum, Germany.

Primary central nervous system lymphoma is a rare but highly aggressive form of non-Hodgkin lymphoma that remains confined to the CNS neuroaxis. The diagnosis of PCNSL requires a high level of suspicion as clinical presentation varies depending on the involved CNS areas. Neurological symptoms and MRI findings may mimic gliomas, demyelinating lesions, or infectious and granulomatous diseases. Read More

View Article and Full-Text PDF